SOTIO Biotech

We will present at the American Association for Cancer Research conference on Tumor-body interactions: The Roles of Micro- and Macroenvironment in Cancer in Boston, MA. Šárka Vošahlíková’s poster will focus on the role of PARP inhibitors for successful immunotherapy in #ovariancancer. #Biotechnology #CancerResearch #jsmePPF

This week, we will attend the Connective Tissue Oncology Society 2024 annual meeting in San Diego. Our Chief Executive Officer, Radek Spisek, Ph.D., and Senior Medical Director, Vivi Boura, MD, PhD, will connect with fellow sarcoma experts and discuss our ongoing efforts in advancing treatments for #sarcoma, such as through our DUET-01 clinical trial studying BOXR1030. #Biotechnology #CancerResearch #jsmePPF

Klára Plačková, junior scientist, is presenting at the INTERNATIONAL PAPILLOMAVIRUS SOCIETY - IPVS Conference in Edinburgh, UK, sharing insights on how tissue structure influences the pattern and density of immune cells that infiltrate tumors in HPV-related cancers. #Biotechnology #CancerResearch #IPVC2024 #jsmePPF

We are presenting a preclinical update on SOT201, a next-generation PD-1-targeting immunocytokine, this week at #SITC24. New data support SOT201’s ability to reinvigorate exhausted immune cells in PD-1 sensitive and resistant tumor models. SOTIO’s two other posters at Society for Immunotherapy of Cancer (SITC) Annual Meeting provide an overview of the ongoing Ph1 clinical trial of SOT201 (VICTORIA-01) and explore the use of a chimeric PGC-1α transgene to enhance CAR T cell activity. Read more in our press release: https://bit.ly/3As1deT #Biotechnology #cancer #CancerResearch #SITC2024 #jsmePPF

#DidYouKnow that #PancreaticCancer is one of the deadliest cancers, with a 5-year survival rate of just 12%? Our Phase 1/2 CLAUDIO-01 trial is currently evaluating SOT102, a Claudin 18.2 ADC, for the treatment of pancreatic cancer. At SOTIO, we’re committed to changing the landscape of #cancer treatment by advancing innovative therapies that aim to improve the lives of patients battling devastating illnesses like pancreatic cancer. Learn more about SOT102 candidate at: https://bit.ly/48CzAfS #PancreaticCancerAwareness #PCAM #Biotechnology #CancerResearch #jsmePPF

Lung cancer is the most common #cancer in men and the second most common in women. As we observe #LungCancerAwarenessMonth, we reaffirm our dedication to advancing therapies for patients facing this significant unmet medical need. #Biotechnology #CancerResearch #jsmePPF

Next month we will be at the World ADC Event Series conference in San Diego. Martin Steegmaier, Chief Scientific Officer, will present on some of the latest progress in our portfolio of #ADC candidates for solid tumors. If you’re attending, be sure to stop by his presentation, or reach out to connect. #WorldADC #Biotechnology #CancerResearch #jsmePPF

Today we had the pleasure of welcoming the new Swiss ambassador, H.E. Urs Bucher, and his embassy colleagues to SOTIO Biotech’s Prague office. Radek Spisek, Pavel Solsky and I gave our guests a tour of our lab space and presented the latest on SOTIO’s efforts to advance #cancer #research. Together with Luděk Sojka Sojka from our affiliate company SCTbio, we also visited lab space that is focused on the manufacturing of #celltherapies. SOTIO is one of the leaders in creating and promoting Czech-Swiss relations. Thank you for your visit and engaging in interesting discussion, Your Excellency! #cancerresearch #Switzerland #jsmePPF

SOTIO will present three posters at the Society for Immunotherapy of Cancer (SITC) Meeting next month in Houston, Texas, including data supporting SOT201, a next-generation PD-1 targeting immunocytokine. Learn more details in our press release: https://bit.ly/48eWZU8 #SITC2024 #Biotechnology #DrugDevelopment #CancerResearch #jsmePPF

Our CEO, Radek Spisek, recently joined the Labiotech.eu #BeyondBiotechpodcast to discuss the pioneering developments in bispecific antibody-drug conjugates (ADCs) and their potential to revolutionize the field of #oncology. On bispecific ADCs, Radek shares: “There are good scientific reasons to believe that there are clinical situations or tumors that make sense to target [two antigens] at the same time, rather than to just go after one.” Tune in to learn more about SOTIO’s ADC platform, including SOT102, now in Phase 1/2 clinical studies in the U.S. and Europe: https://bit.ly/4eLwp7I #ADC #biotechnology #jsmePPF